{
  "id": "CD012532.PUB2",
  "draft": "Are anti-PD-1 and anti-PD-L1 therapies effective for treating glioma? \n- Therapies called anti-PD-1 and anti-PD-L1 may not be effective for treating glioma. Most studies showed these treatments did not help people live longer (overall survival) or stop the disease from getting worse (progression-free survival). However, the evidence we have is not strong enough to be certain.\n- The evidence for the effectiveness of these therapies in treating glioma is generally of low quality. We need more research to be sure about the benefits and harms of these treatments. This is especially true for different groups, like people who were just diagnosed or whose cancer has returned.\n- Future studies should aim to provide higher-quality evidence about these treatments. We need to be more certain about their effects on a person’s quality of life (overall well-being) and their risk of serious side effects.\n\nWhat is glioblastoma multiforme and why is it a problem?\nGlioblastoma multiforme is the most common and aggressive type of adult glioma (a kind of brain tumor). It has a poor prognosis, with a median survival of only 16 months. The tumor’s environment weakens the immune system, making it hard for the body to fight the cancer. Today’s treatments don’t work as well as we’d like, so we need to find new ways to help people live longer and feel better.\n\nWhat are immune checkpoint inhibitors and how do they work?\nImmune checkpoint inhibitors are a type of cancer treatment that helps the immune system recognize and attack cancer cells. They work by blocking specific proteins, such as PD-1 and PD-L1, that cancer cells use to evade the immune system. By blocking these proteins, immune checkpoint inhibitors allow the immune system to target and destroy cancer cells more effectively.\n\nWhat did the review authors want to find out?\nWe wanted to assess the effects of immune checkpoint inhibitors, specifically anti-PD-1 and anti-PD-L1 antibodies, in treating adults with diffuse glioma. We aimed to determine whether these treatments can improve overall survival, progression-free survival, and quality of life, while also examining their potential side effects.\n\nWhat did we find?\nWe found 7 studies that involved 1953 people with diffuse glioma. Most studies looked at an anti-PD-1 treatment for people with grade 4 glioma (the most aggressive type). Some people in the studies had just been diagnosed with the cancer, while for others it had come back after treatment. The studies compared anti-PD-1/PD-L1 antibodies to placebo or other therapies used alone or with other immune checkpoint inhibitors. Our main findings were:\n- For people whose cancer has returned: A drug called nivolumab probably offers no benefit. Combining other similar drugs with bevacizumab may also be ineffective.\n- For people who are newly diagnosed: Adding nivolumab to radiotherapy probably has no benefit.\n- For older people: Adding nivolumab after initial treatment probably offers no benefit.\n\nWhat are the limitations of the evidence?\nThe evidence is limited by very small study sizes, possible lack of blinding (participants may have known their treatment), and the studies did not always report on the results we were looking for. These limitations matter because they can affect the reliability and accuracy of the findings, making it harder to draw firm conclusions about the effectiveness of anti-PD-1 and anti-PD-L1 therapies for glioma.\n\nIs the evidence up to date?\nThe evidence is up to date to March 2024.\n\nHow did we find this information?\nWe searched for studies comparing anti-PD-1 and anti-PD-L1 antibodies to other treatments in adults with diffuse glioma, summarized their results, and rated our confidence in the evidence.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 648,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 36,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 18,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 13,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 66,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 38,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 16,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 176,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 176.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 60.881666666666675,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 9.23925925925926,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 9.077546296296298,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 9.40574074074074,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 13.434567901234567,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 41.76543209876543,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 4.277777777777778,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 12.643650760992955,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 6.862784567901236,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 245,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 245.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 101,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 154,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 648,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 648 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 8,
        "P50_count": 1,
        "P75_count": 7,
        "P90_count": 2,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 44.44444444444444,
        "P50_percentage": 5.555555555555555,
        "P75_percentage": 38.88888888888889,
        "P90_percentage": 11.11111111111111,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 83.33333333333334,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This is a strong draft that is factually accurate and well-structured. However, it needs a few revisions to improve clarity for a lay audience before it can be approved. Here are the top 3 improvements needed:\n\n1. **Explain technical terms in the title and key messages.** The title and first key message use 'anti-PD-1' and 'anti-PD-L1' without explaining what they are. This can confuse readers from the start.\n   - **Problem:** \"Are anti-PD-1 and anti-PD-L1 therapies effective for treating glioma?\"\n   - **Suggestion:** Add the plain language explanation from the source material to provide immediate context. Rewrite the title as: \"Are anti-PD-1 and anti-PD-L1 therapies (which help the immune system fight cancer) effective for treating glioma (a type of brain tumor)?\"\n\n2. **Clarify vague language in the results.** The summary of findings for recurrent cancer is a bit too simple and loses important nuance from the original abstract.\n   - **Problem:** \"Combining other similar drugs with bevacizumab may also be ineffective.\"\n   - **Suggestion:** Be more specific and accurately reflect the uncertainty mentioned in the source. A better summary would be: \"Combining another drug (pembrolizumab) with bevacizumab may also be ineffective. One very small study suggested giving pembrolizumab before and after surgery might help people live longer, but the evidence was very uncertain.\"\n\n3. **Simplify noun-heavy sentences.** Some sentences rely on multiple abstract nouns, which can make them harder to read. This is reflected in the linguistic analysis, which shows a high noun count.\n   - **Problem:** \"These limitations matter because they can affect the reliability and accuracy of the findings, making it harder to draw firm conclusions about the effectiveness of anti-PD-1 and anti-PD-L1 therapies for glioma.\"\n   - **Suggestion:** Break this into shorter, more active sentences. For example: \"These limitations are important. They make the results less reliable, so we cannot be certain about how well these therapies work for glioma.\"",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns, with 83% of metrics falling in the best quartile for readability and sentence structure. However, it deviates with a high number of nouns (176.0, P90) and Dale-Chall complex words (245.0, P90). This supports the editorial feedback that some sentences are noun-heavy and could be simplified to improve clarity for a lay audience."
    }
  ]
}